vs
Amneal Pharmaceuticals, Inc.（AMRX）与FIVE BELOW, INC（FIVE）财务数据对比。点击上方公司名可切换其他公司
FIVE BELOW, INC的季度营收约是Amneal Pharmaceuticals, Inc.的1.3倍（$1.0B vs $814.3M），Amneal Pharmaceuticals, Inc.净利率更高（4.3% vs 3.5%，领先0.8%），FIVE BELOW, INC同比增速更快（23.1% vs 11.5%），Amneal Pharmaceuticals, Inc.自由现金流更多（$108.5M vs $-133.2M），过去两年Amneal Pharmaceuticals, Inc.的营收复合增速更高（11.1% vs -11.9%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
Five Below是美国特色折扣礼品连锁品牌，2002年成立，总部位于宾夕法尼亚州费城，主要面向青少年消费群体，旗下绝大多数商品定价不超过5美元，另有少量精选商品最高定价40美元，目前在全美拥有超过1850家线下门店。
AMRX vs FIVE — 直观对比
营收规模更大
FIVE
是对方的1.3倍
$814.3M
营收增速更快
FIVE
高出11.6%
11.5%
净利率更高
AMRX
高出0.8%
3.5%
自由现金流更多
AMRX
多$241.7M
$-133.2M
两年增速更快
AMRX
近两年复合增速
-11.9%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $1.0B |
| 净利润 | $35.1M | $36.5M |
| 毛利率 | 36.5% | 33.8% |
| 营业利润率 | 13.8% | 4.2% |
| 净利率 | 4.3% | 3.5% |
| 营收同比 | 11.5% | 23.1% |
| 净利润同比 | 212.9% | 2063.9% |
| 每股收益（稀释后） | $0.10 | $0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXFIVE
| Q4 25 | $814.3M | $1.0B | ||
| Q3 25 | $784.5M | $1.0B | ||
| Q2 25 | $724.5M | $970.5M | ||
| Q1 25 | $695.4M | $1.4B | ||
| Q4 24 | $730.5M | $843.7M | ||
| Q3 24 | $702.5M | $830.1M | ||
| Q2 24 | $701.8M | $811.9M | ||
| Q1 24 | $659.2M | $1.3B |
净利润AMRXFIVE
| Q4 25 | $35.1M | $36.5M | ||
| Q3 25 | $2.4M | $42.8M | ||
| Q2 25 | $22.4M | $41.1M | ||
| Q1 25 | $12.2M | $187.5M | ||
| Q4 24 | $-31.1M | $1.7M | ||
| Q3 24 | $-156.0K | $33.0M | ||
| Q2 24 | $6.0M | $31.5M | ||
| Q1 24 | $-91.6M | $202.2M |
毛利率AMRXFIVE
| Q4 25 | 36.5% | 33.8% | ||
| Q3 25 | 34.9% | 33.3% | ||
| Q2 25 | 39.5% | 33.4% | ||
| Q1 25 | 36.8% | 40.2% | ||
| Q4 24 | 36.0% | 30.6% | ||
| Q3 24 | 38.4% | 32.7% | ||
| Q2 24 | 35.6% | 32.5% | ||
| Q1 24 | 36.1% | 41.2% |
营业利润率AMRXFIVE
| Q4 25 | 13.8% | 4.2% | ||
| Q3 25 | 9.0% | 5.1% | ||
| Q2 25 | 15.4% | 5.2% | ||
| Q1 25 | 14.4% | 17.7% | ||
| Q4 24 | 10.4% | -0.1% | ||
| Q3 24 | 12.6% | 5.0% | ||
| Q2 24 | 13.6% | 4.5% | ||
| Q1 24 | -1.6% | 20.1% |
净利率AMRXFIVE
| Q4 25 | 4.3% | 3.5% | ||
| Q3 25 | 0.3% | 4.2% | ||
| Q2 25 | 3.1% | 4.2% | ||
| Q1 25 | 1.8% | 13.5% | ||
| Q4 24 | -4.3% | 0.2% | ||
| Q3 24 | -0.0% | 4.0% | ||
| Q2 24 | 0.9% | 3.9% | ||
| Q1 24 | -13.9% | 15.1% |
每股收益（稀释后）AMRXFIVE
| Q4 25 | $0.10 | $0.66 | ||
| Q3 25 | $0.01 | $0.77 | ||
| Q2 25 | $0.07 | $0.75 | ||
| Q1 25 | $0.04 | $3.40 | ||
| Q4 24 | $-0.10 | $0.03 | ||
| Q3 24 | $0.00 | $0.60 | ||
| Q2 24 | $0.02 | $0.57 | ||
| Q1 24 | $-0.30 | $3.64 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | $524.5M |
| 总债务越低越好 | $2.6B | — |
| 股东权益账面价值 | $-70.8M | $2.0B |
| 总资产 | $3.7B | $4.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRXFIVE
| Q4 25 | $282.0M | $524.5M | ||
| Q3 25 | $201.2M | $670.2M | ||
| Q2 25 | $71.5M | $624.0M | ||
| Q1 25 | $59.2M | $528.8M | ||
| Q4 24 | $110.6M | $216.6M | ||
| Q3 24 | $74.0M | $327.7M | ||
| Q2 24 | $43.8M | $369.6M | ||
| Q1 24 | $46.5M | $460.1M |
总债务AMRXFIVE
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.4B | — |
股东权益AMRXFIVE
| Q4 25 | $-70.8M | $2.0B | ||
| Q3 25 | $-109.5M | $1.9B | ||
| Q2 25 | $-112.1M | $1.9B | ||
| Q1 25 | $-131.7M | $1.8B | ||
| Q4 24 | $-109.3M | $1.6B | ||
| Q3 24 | $-93.4M | $1.6B | ||
| Q2 24 | $-57.5M | $1.6B | ||
| Q1 24 | $-63.7M | $1.6B |
总资产AMRXFIVE
| Q4 25 | $3.7B | $4.8B | ||
| Q3 25 | $3.6B | $4.6B | ||
| Q2 25 | $3.4B | $4.5B | ||
| Q1 25 | $3.4B | $4.3B | ||
| Q4 24 | $3.5B | $4.2B | ||
| Q3 24 | $3.5B | $4.0B | ||
| Q2 24 | $3.5B | $3.9B | ||
| Q1 24 | $3.5B | $3.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | $-80.1M |
| 自由现金流经营现金流 - 资本支出 | $108.5M | $-133.2M |
| 自由现金流率自由现金流/营收 | 13.3% | -12.8% |
| 资本支出强度资本支出/营收 | 2.7% | 5.1% |
| 现金转化率经营现金流/净利润 | 3.72× | -2.19× |
| 过去12个月自由现金流最近4个季度 | $269.9M | $323.0M |
8季度趋势，按日历期对齐
经营现金流AMRXFIVE
| Q4 25 | $130.3M | $-80.1M | ||
| Q3 25 | $118.5M | $93.0M | ||
| Q2 25 | $83.8M | $132.7M | ||
| Q1 25 | $7.4M | $363.5M | ||
| Q4 24 | $118.1M | $-30.6M | ||
| Q3 24 | $141.8M | $71.3M | ||
| Q2 24 | $39.7M | $26.4M | ||
| Q1 24 | $-4.4M | $407.7M |
自由现金流AMRXFIVE
| Q4 25 | $108.5M | $-133.2M | ||
| Q3 25 | $106.2M | $48.3M | ||
| Q2 25 | $61.0M | $96.5M | ||
| Q1 25 | $-5.8M | $311.4M | ||
| Q4 24 | $102.9M | $-111.0M | ||
| Q3 24 | $124.8M | $-32.4M | ||
| Q2 24 | $29.0M | $-61.4M | ||
| Q1 24 | $-13.6M | $304.6M |
自由现金流率AMRXFIVE
| Q4 25 | 13.3% | -12.8% | ||
| Q3 25 | 13.5% | 4.7% | ||
| Q2 25 | 8.4% | 9.9% | ||
| Q1 25 | -0.8% | 22.4% | ||
| Q4 24 | 14.1% | -13.2% | ||
| Q3 24 | 17.8% | -3.9% | ||
| Q2 24 | 4.1% | -7.6% | ||
| Q1 24 | -2.1% | 22.8% |
资本支出强度AMRXFIVE
| Q4 25 | 2.7% | 5.1% | ||
| Q3 25 | 1.6% | 4.4% | ||
| Q2 25 | 3.2% | 3.7% | ||
| Q1 25 | 1.9% | 3.7% | ||
| Q4 24 | 2.1% | 9.5% | ||
| Q3 24 | 2.4% | 12.5% | ||
| Q2 24 | 1.5% | 10.8% | ||
| Q1 24 | 1.4% | 7.7% |
现金转化率AMRXFIVE
| Q4 25 | 3.72× | -2.19× | ||
| Q3 25 | 50.00× | 2.17× | ||
| Q2 25 | 3.74× | 3.22× | ||
| Q1 25 | 0.61× | 1.94× | ||
| Q4 24 | — | -18.13× | ||
| Q3 24 | — | 2.16× | ||
| Q2 24 | 6.62× | 0.84× | ||
| Q1 24 | — | 2.02× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
FIVE
暂无分部数据
